Initial concerns were raised after findings from the cardiovascular outcome trial (CVOT), Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes 6 (SUSTAIN 6), revealed a greater risk of DR-related complications, defined as the need for laser therapy, intravitreal injections, development of vitreous hemorrhage, and blindness, in semaglutide users compared to placebo (3.0% vs 1.8%, HR=1.76, P =.02)
Those numbers mean most patients will not develop persistent arrhythmias, but if palpitations are accompanied by chest pain, fainting, or breathlessness, treat them as urgent
They stimulate GH release through two complementary pathways: GHRH receptor and ghrelin (GHS-R) receptor
Comparative Effects of Two Different Forms of Selenium on Oxidative Stress Biomarkers in Healthy Men: A Randomized Clinical Trial